EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Personalized neoantigen cancer vaccines: current progression, challenges and a bright future

Da-Wei Wu, Shuo-Peng Jia, Shu-Jun Xing, Hai-Lan Ma, Xin Wang, Qi-Yu Tang, Zi-Wei Li, Qing Wu, Min Bai, Xin-Yong Zhang, Xiao-Feng Fu, Ming-Ming Jia und 3 weitere

Clinical and Experimental Medicine · 26.09.2024 · 24 (1)

DOI: 10.1007/s10238-024-01436-7 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical and Experimental Medicine, online erschienen am 26.09.2024. Verfasst von Da-Wei Wu und 14 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Trials Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and …. Hauptthemen laut MEDLINE: Cancer Vaccines, Antigens, Neoplasm, Precision Medicine, Neoplasms. Die Arbeit wurde bisher 69-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Beijing Hope Run Special Fund of Cancer Foundation of China, Beijing Natural Science Foundation, The Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences (Construction and Application of Clinical Trial and Institution Evaluation System).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tumor neoantigens possess specific immunogenicity and personalized therapeutic vaccines based on neoantigens which have shown promising results in some clinical trials, with broad application prospects. However, the field is developing rapidly and there are currently few relevant review articles. Summarizing and analyzing the status of global personalized neoantigen vaccine clinical trials will provide important data for all stakeholders in drug development. Based on the Trialtrove database, a retrospective analysis was conducted using trial quantity as a key indicator for neo-adjuvant and adjuvant therapy anti-PD-1/PD-L1 clinical trials initiated before the end of 2022. The time trend of newly initiated trials was investigated. The sponsor type, host country, treatment mode, combination strategy, tested drugs, and targeted cancer types of these trials were summarized. As of December 2022, a total of 199 trials were included in the analysis. Among these studies, Phase I studies were the most numerous (119, 59.8%), and Phase I studies have been the predominant study type since 2015. Peptide vaccines were the largest neoantigen vaccines type, accounting for 64.8% of all clinical trials. Based on peptide delivery platforms, the proportion of trials was highest for the DC system (32, 16.1%), followed by LNP (11, 5.5%), LPX (11, 5.5%), and viruses (7, 3.5%). Most vaccines were applied in trials as a monotherapy (133/199, 66.8%), meanwhile combining immunotherapeutic drugs was the most common form for combination therapy. In terms of indications, the largest number of trials involved three or more unspecified solid tumors (50/199, 25.1%), followed by non-small cell lung cancer (24/199, 12.1%) and pancreatic cancer (15/199, 7.5%). The clinical development of personalized neoantigen cancer vaccines is still in the early stage. A clear shift in delivery systems from peptides to DC and liposomal platforms, with the largest number of studies in Asia, collectively marks a new era in the field. The adjuvant or maintenance therapy, and the combination treatment with ICIs are becoming the important clinical development orientation. As research on tumor–immune interactions intensifies, the design, development, and application of neoantigen vaccines are bound to develop rapidly, which will bring a new revolution in the future cancer treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cancer VaccinesAntigens, NeoplasmPrecision MedicineNeoplasmsHumansClinical Trials as TopicRetrospective StudiesImmunotherapy

Stichwörter der Autor:innen

Clinical trialNeoantigen vaccinesPersonalizedSolid tumor

Substanzen

Cancer VaccinesAntigens, Neoplasm

Autor:innen und Institutionen

  • Clinical Trials Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
  • Clinical Trials Center, Shanxi Province Cancer Hospital/Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan, 030013, China.
  • Department of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, 211198, China.
  • Department of Hematology, Shanxi Province Cancer Hospital/Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan, 030013, Chin…
  • Department of Medical Oncology, Beijing Chest Hospital of Capital Medical University, Beijing, 100021, China.
  • Beijing Likang Life Science, Beijing, 100000, China.

Förderung

  • Beijing Hope Run Special Fund of Cancer Foundation of China
  • Beijing Natural Science Foundation
  • The Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences (Construction and Application of Clinical Trial and Institution Evaluation System)

Zitieren

APA

Wu, D. W., Jia, S. P., Xing, S. J., Ma, H. L., Wang, X., Tang, Q. Y., Li, Z. W., Wu, Q., Bai, M., Zhang, X. Y., Fu, X. F., Jia, M. M., Tang, Y., Chen, L., & Li, N. (2024). Personalized neoantigen cancer vaccines: current progression, challenges and a bright future. Clinical and Experimental Medicine, 24(1). https://doi.org/10.1007/s10238-024-01436-7

Vancouver

Wu DW, Jia SP, Xing SJ, Ma HL, Wang X, Tang QY, et al. Personalized neoantigen cancer vaccines: current progression, challenges and a bright future. Clinical and Experimental Medicine. 2024;24(1). doi:10.1007/s10238-024-01436-7

BibTeX
@article{Wu2024,
  author = {Wu, Da-Wei and Jia, Shuo-Peng and Xing, Shu-Jun and Ma, Hai-Lan and Wang, Xin and Tang, Qi-Yu and Li, Zi-Wei and Wu, Qing and Bai, Min and Zhang, Xin-Yong and Fu, Xiao-Feng and Jia, Ming-Ming and Tang, Yu and Chen, Li and Li, Ning},
  title = {Personalized neoantigen cancer vaccines: current progression, challenges and a bright future},
  journal = {Clinical and Experimental Medicine},
  year = {2024},
  volume = {24},
  number = {1},
  doi = {10.1007/s10238-024-01436-7}
}
Kostenlos starten →